Press and Publications
We'd love to tell you more about what we do at Phaim and how we look to develop treatments that change how we prevent and treat type 1 diabetes as well as other autoimmune diseases.
YouTube VideoPhaim Pharma poised to trial drug that resets immune system to treat T1D.
In The NewsA novel method assessing the success of any diabetes intervention therapy published in 2020.
EditorialBackground to AIM
Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1.
Read HereAutoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.
Read HereReduction in CD4 Central Memory T-Cell Subset in Costimulation Modulator Abatacept-Treated Patients With Recent-Onset Type 1 Diabetes Is Associated With Slower C-Peptide Decline.
Read HereAntigen-based therapy with glutamic acid decarboxylase (GAD) AIM therapy in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Read HereExtreme Th1 bias of invariant V24JQ T cells in type 1 diabetes.
Read HereMutations in NEUROD1 are associated with the development of type 2 diabetes mellitus.
Read HereConcordance for Islet Autoimmunity among Monozygotic Twins.
Read HereNew hope for immune intervention therapy in type 1 diabetes.
Read HereCurrent Publications supporting AIM
A Novel Quantitative Approach to Staging and Assessing Recovery from Type 1 Diabetes Mellitus: The Type 1 Diabetes Mellitus Metabolic Recovery Index.
Read HereAntigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity.
Read HereImplanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C- peptide in patients with type 1 diabetes.
Read HereInsulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device.
Read Here